← All trials
NCT06701149
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 28, 2024
- Primary completion
- Feb 28, 2025
- Completion date
- Mar 31, 2025
- First posted
- Nov 22, 2024
- Last posted
- Nov 22, 2024
- Enrollment
- 178
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Simcere Pharmaceutical Co., LtdLead sponsor
- Jinan UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.